| Ms Tiffany Thomas, | |
|
1005 Atlantic Ave, Alameda, CA 94501-1148 | |
| (510) 422-9449 | |
| (510) 878-7345 |
| Full Name | Ms Tiffany Thomas |
|---|---|
| Gender | Female |
| Speciality | Student In An Organized Health Care Education/training Program |
| Location | 1005 Atlantic Ave, Alameda, California |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598211260 | NPI | - | NPPES |
| 1411033663 | Other | CA | EMPLOYER IDENTIFICATION NUMBER |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YM0800X | Counselor - Mental Health | (* (Not Available)) | Secondary |
| 390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Ms Tiffany Thomas, 1005 Atlantic Ave, Alameda, CA 94501-1148 Ph: (510) 422-9449 | Ms Tiffany Thomas, 1005 Atlantic Ave, Alameda, CA 94501-1148 Ph: (510) 422-9449 |
News Archive
A University of Michigan Health System-led team of researchers has found a biomarker they believe can help rapidly identify one of the most serious complications in patients with leukemia, lymphoma and other blood disorders who have received a transplant of new, blood-forming cells.
While the Unites States Congress is busy debating the high costs of health care reform, TreatmentReport.com aims to promote health system efficiency by making treatment information structured and transparent. On the site, people with health conditions can review and share treatment experiences with those researching their options.
While employers may celebrate a low absenteeism rate among their employees, there may be a more serious problem if sick employees are coming to work. "Presenteeism," a new term coined for when employees work while unhealthy, may be even worse for employers and for the healthcare system, costing $160 billion annually in lost productivity, according to healthcare market research firm Kalorama Information, in its new report "The Market for Wellness Programs and Their Impact on Pharmaceutical, Diagnostic and Device Product Markets." The report also notes that presenteeism costs are one of many factors driving usage of wellness programs.
Incyte Corporation announced today additional positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 66 patients with HER2-positive metastatic breast cancer during a poster session at the American Society of Clinical Oncology (ASCO) meeting in Chicago, IL, June 4 to June 8, 2010.
Novartis announced today that the US Food and Drug Administration has approved Promacta (eltrombopag) for the treatment of children six years and older with chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Promacta was approved by the FDA in 2008 for use in adult patients with the same condition.
› Verified 5 days ago